Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Colin R Goding

Showing results (111-120 of 126) with videos related to

Pageof 13
Sort By:
Nature Communications|December 16, 2014
Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanomaJudith Müller, Oscar Krijgsman, Jennifer Tsoi, et al.
Genes & Development|January 19, 2017
Translation reprogramming is an evolutionarily conserved driver of phenotypic plasticity and therapeutic resistance in melanomaPaola Falletta, Luis Sanchez-Del-Campo, Jagat Chauhan, et al.
Cancer Cell|April 30, 2013
Restoring p53 function in human melanoma cells by inhibiting MDM2 and cyclin B1/CDK1-phosphorylated nuclear iASPPMin Lu, Hilde Breyssens, Victoria Salter, et al.
Nature Communications|November 29, 2017
Stem cell senescence drives age-attenuated induction of pituitary tumours in mouse models of paediatric craniopharyngiomaJose Mario Gonzalez-Meljem, Scott Haston, Gabriela Carreno, et al.
Cancer Cell|November 16, 2016
Restoring p53 Function in Human Melanoma Cells by Inhibiting MDM2 and Cyclin B1/CDK1-Phosphorylated Nuclear iASPPMin Lu, Hilde Breyssens, Victoria Salter, et al.
Nature Reviews. Cancer|March 25, 2016
The importance of p53 pathway genetics in inherited and somatic cancer genomesGiovanni Stracquadanio, Xuting Wang, Marsha D Wallace, et al.
Pharmacological Research|September 24, 2021
TOP1 modulation during melanoma progression and in adaptative resistance to BRAF and MEK inhibitorsÉrica Aparecida de Oliveira, Jagat Chauhan, Julia Rezende da Silva, et al.
Molecular Cell|June 13, 2020
Tuning Transcription Factor Availability through Acetylation-Mediated Genomic RedistributionPakavarin Louphrasitthiphol, Robert Siddaway, Alessia Loffreda, et al.
Cell Reports|November 23, 2025
MITF, TFEB, and TFE3 drive distinct adaptive gene expression programs and immune infiltration in melanomaDiogo Dias, Erica Oliveira, Román Martí-Díaz, et al.
Nature Communications|June 18, 2021
BRN2 is a non-canonical melanoma tumor-suppressorMichael Hamm, Pierre Sohier, Valérie Petit, et al.
Pageof 13

Showing results (111-120 of 126) with videos related to

Sort By:
Pageof 13
Nature Communications|December 16, 2014
Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanomaJudith Müller, Oscar Krijgsman, Jennifer Tsoi, et al.
Genes & Development|January 19, 2017
Translation reprogramming is an evolutionarily conserved driver of phenotypic plasticity and therapeutic resistance in melanomaPaola Falletta, Luis Sanchez-Del-Campo, Jagat Chauhan, et al.
Cancer Cell|April 30, 2013
Restoring p53 function in human melanoma cells by inhibiting MDM2 and cyclin B1/CDK1-phosphorylated nuclear iASPPMin Lu, Hilde Breyssens, Victoria Salter, et al.
Nature Communications|November 29, 2017
Stem cell senescence drives age-attenuated induction of pituitary tumours in mouse models of paediatric craniopharyngiomaJose Mario Gonzalez-Meljem, Scott Haston, Gabriela Carreno, et al.
Cancer Cell|November 16, 2016
Restoring p53 Function in Human Melanoma Cells by Inhibiting MDM2 and Cyclin B1/CDK1-Phosphorylated Nuclear iASPPMin Lu, Hilde Breyssens, Victoria Salter, et al.
Nature Reviews. Cancer|March 25, 2016
The importance of p53 pathway genetics in inherited and somatic cancer genomesGiovanni Stracquadanio, Xuting Wang, Marsha D Wallace, et al.
Pharmacological Research|September 24, 2021
TOP1 modulation during melanoma progression and in adaptative resistance to BRAF and MEK inhibitorsÉrica Aparecida de Oliveira, Jagat Chauhan, Julia Rezende da Silva, et al.
Molecular Cell|June 13, 2020
Tuning Transcription Factor Availability through Acetylation-Mediated Genomic RedistributionPakavarin Louphrasitthiphol, Robert Siddaway, Alessia Loffreda, et al.
Cell Reports|November 23, 2025
MITF, TFEB, and TFE3 drive distinct adaptive gene expression programs and immune infiltration in melanomaDiogo Dias, Erica Oliveira, Román Martí-Díaz, et al.
Nature Communications|June 18, 2021
BRN2 is a non-canonical melanoma tumor-suppressorMichael Hamm, Pierre Sohier, Valérie Petit, et al.
Pageof 13